RxDoctor Payments Data

Sumitha Panicker, MD

Internal Medicine · Bolingbrook, ILNPI 1528279577

Payments from drug & device makers

$9,035in general payments, 2019–2025

Across 508 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$906
  • Kerecis Limited$749
  • Novo Nordisk$676
  • Bayer$652
  • AbbVie$456
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,93599%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,035 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$108,144
Medicare patients
205
Services billed
1,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$40,205
FarxigaDapagliflozin Propanediol27$30,048
EliquisApixaban27$19,094
JardianceEmpagliflozin14$18,074
TradjentaLinagliptin32$13,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,190
MyrbetriqMirabegron11$5,072
Gentamicin Sulfate118$4,820
Nebivolol Hcl14$3,147
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$1,771
Rosuvastatin Calcium75$1,747
Atorvastatin Calcium109$1,564
Memantine Hcl41$1,159
Albuterol Sulfate HfaAlbuterol Sulfate23$1,155
Finasteride32$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,401$40,20535 claims
Boehringer IngelheimJardiance, Tradjenta$85$31,62546 claims
AstraZenecaFarxiga$906$30,04827 claims
PfizerEliquis$114$19,09427 claims
GSKTrelegy Ellipta$96$13,19016 claims
Astellas Pharma US IncMyrbetriq$278$5,07211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Bolingbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →